Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Excalibur To Test AZ Compound In Diabetics With COVID-19

Potential Benefits Include Reduced Incidence Of ARDS

Executive Summary

A randomized double-blind study will look at whether a glucokinase activator in addition to usual care can help improve clinical outcomes in type 1 and 2 diabetes patients with coronavirus symptoms. 

You may also be interested in...



Coronavirus Notebook: EU In More Vaccine Talks, HTA Rolling Reviews, and RECOVERY’s UK Expansion

The European Commission is in talks to buy vaccines from CureVac and Moderna, amid concerns over “vaccine nationalism” and lack of transparency. Meanwhile the EU health technology assessment network has begun publishing “rolling collaborative reviews” of potential COVID-19 therapies, and two more firms have announced progress with monoclonal antibodies. 

Brexit: New Rules Will Hit Parallel Trade From UK to EU

Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway 

Radical Shake-Up In Store For Entire EU Pharma Legislation

The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel